Latest News Releases
RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.
- RedHill Biopharma Ltd.
The second dose of a COVID-19 vaccine induces a powerful boost to a part of the immune system that provides broad antiviral protection, according to a study led by investigators at the Stanford University School of Medicine.
University of Minnesota School of Public Health researchers recently completed a study to determine how food-insecure young (emerging) adults (18-29 years of age) adapted their eating and child feeding behaviors during the COVID-19 pandemic. The researchers also sought to identify barriers to food access and opportunities to improve local access to resources for emerging adults. Their study results are published in the Journal of the Academy of Nutrition and Dietetics.
- Journal of the Academy of Nutrition and Dietetics
- , Lung, NIH/National Heart, Lung and Blood Institute
Using data from 9,859 COVID-19 infections, Mayo Clinic researchers have new insights into risk factors for younger populations, some of which differ significantly from their older counterparts. People younger than 45 had a greater than threefold increased risk of severe infection if they had cancer or heart disease, or blood, neurologic or endocrine disorders, the research found. These associations were weaker in older age groups. The study was published in Mayo Clinic Proceedings.
- Mayo Clinic Proceedings
- Mayo Clinic COVID-19 Research Fund, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
An observational study in Barcelona, Spain found that implementation of same-day rapid screening, use of face masks, and improved ventilation was associated with very low rates of SARS-CoV-2 transmission at an indoor mass-gathering live concert without physical distancing. The brief research report is published in Annals of Internal Medicine.
- Annals of Internal Medicine
Research led by the University of Southampton into the uptake of the COVID-19 vaccine in Ghana, West Africa has concluded that vaccine hesitancy has seen a small, but significant increase over the last three months. This research is in collaboration with youth-led not-for-profit organisation PACKS Africa.
Scientists from three national labs have published a comprehensive study that - alongside other recent, complementary studies of coronavirus proteins and genetics - represents the first step toward developing treatments for COVID-19.
- Biophysical Journal
A team of researchers from the University of Bern and the Institute of Virology and Immunology (IVI) have used a unique collection of advanced cell culture models of cells lining the airways from various domesticated and wildlife animals to determine which animals are susceptibly to SARS-CoV-2 infection. The team found that SARS-CoV-2 efficiently infected respiratory cells from monkey and cats, and proposes that SARS-CoV-2 surveillance in these animals and its close relatives is necessary.
- Emerging Infectious Diseases
- Swiss Federal Food Safety and Veterinary Office, European Commission (Marie Sklodowska-Curie Innovative Training Network "HONOURS"), Swiss National Science Foundation SNSF (Special call on Coronaviruses), German Federal Ministry of Education and Research
Although people in early 2020 were highly cautious about COVID-19, 11 months later the public pushed the envelope on pandemic safety precautions and ignored warnings as time went on, a new University of California, Davis, study suggests.
We must not assume that we will be able to replicate a vaccine within 12 months during the next pandemic. Even if this was accomplished, other interventions would be required to control and mitigate well before the availability of a vaccine.
- Disaster Medicine and Public Health Preparedness
An international team of researchers led by Kumamoto and Tokyo Universities (Japan) have shown that the L452R mutation of the SARS-CoV-2 spike protein, which is common to two variants (Epsilon and Delta), is involved in cellular immunity evasion via the human leukocyte antigen (HLA) A24, and enhances viral infectivity. HLA-A24 is one of the most prominent HLA-class I alleles, especially in East/Southeast Asian populations, which might make them particularly vulnerable to variants with the mutation.
- Cell Host & Microbe
- 2) AMED Research Program on HIV/AIDS, 4) JST A-STEP, 5) JST J-RAPID, 6) JST SICORP (e-ASIA), and others, 3) AMED Japan Program for Infectious Diseases Research and Infrastructure, 1) AMED Research Program on Emerging and Re-emerging Infectious Diseases
A coronavirus related to the virus that causes Covid-19 in humans has been found in UK horseshoe bats. However, there is no evidence that this novel virus has been transmitted to humans, or that it could in future, unless it mutates.
- Scientific Reports
Researchers at Michigan Medicine have discovered another functional autoantibody in COVID-19 patients that contributes to the disease's development and the "firestorm" of blood clots and inflammation it induces. The autoantibody makes it much harder for the body to degrade neutrophil extracellular traps, the toxic webs of DNA and proteins produced by overactive immune cells at heightened levels in COVID patients.
- JCI Insight
Researchers are using computer models to simulate COVID-19 infections on a cellular level which allows for virtual trials of drugs and vaccines, opening the possibility of pre-assessment for drug and vaccine efficacy against the virus.